ONCT News and Press, Oncternal Therapeutics Inc. From 03/09/23

2023-03-09 21:19:05 ET Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Conference Call March 09, 2023, 05:00 PM ET Company Participants James Breitmeyer - President and CEO Richard Vincent - CFO Salim Yazji - Chief Medical Officer Conference Call Parti...

2023-03-09 16:03:27 ET Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q4 GAAP EPS of -$0.20 beats by $0.01 . Revenue of $0.17M misses by $0.11M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.20 beats by $0.01, revenue of $0.17M ...

Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December 2022 Zilovertamab global Phase 3 registrational Study ZILO-301 for the treatment of patie...

2023-03-08 17:35:28 ET Major earnings expected after the bell on Thursday include: Oracle corporation ( ORCL ) DocuSign ( DOCU ) Wheaton Precious Metals Corp. ( WPM ) Bionano Genomics ( BNGO ) Ulta Beauty  (ULTA0) For further details see: ...

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S. fina...

Summary As ONCT's MCL Phase 2 study continues to mature, the data also continues to improve.  In fact, the data now looks outstanding. Thus, I believe that the chances of success in the newly initiated Phase 3 trial are good and hence I rate the stock as a buy at today's stock pric...

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors. “We are thrilled to...

Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reporting The ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of ...

Oncternal Therapeutics, Inc. (ONCT) Q3 2022 Earnings Conference Call November 03, 2022, 05:00 PM ET Company Participants Rich Vincent - Chief Financial Officer Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call ...

Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q3 GAAP EPS of -$0.21 (vs. -$0.19 Y/Y) beats by $0.03 . Revenue of $0.38M (-81.9% Y/Y) beats by $0.13M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $...